Kestra Advisory Services LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 28.5% during the 1st quarter, HoldingsChannel reports. The fund owned 3,534 shares of the medical equipment provider’s stock after buying an additional 783 shares during the period. Kestra Advisory Services LLC’s holdings in Hologic were worth $271,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Stratos Wealth Partners LTD. bought a new position in shares of Hologic during the first quarter worth about $214,000. Robeco Institutional Asset Management B.V. grew its position in shares of Hologic by 405.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 414,787 shares of the medical equipment provider’s stock worth $31,864,000 after acquiring an additional 332,706 shares during the last quarter. Tobam grew its position in shares of Hologic by 25.4% during the first quarter. Tobam now owns 1,102 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 223 shares during the last quarter. WoodTrust Financial Corp grew its position in shares of Hologic by 24.8% during the first quarter. WoodTrust Financial Corp now owns 17,225 shares of the medical equipment provider’s stock worth $1,323,000 after acquiring an additional 3,425 shares during the last quarter. Finally, Pendal Group Ltd grew its position in shares of Hologic by 22.9% during the first quarter. Pendal Group Ltd now owns 13,059 shares of the medical equipment provider’s stock worth $1,003,000 after acquiring an additional 2,434 shares during the last quarter. 92.70% of the stock is owned by institutional investors and hedge funds.
Hologic Price Performance
Shares of NASDAQ HOLX opened at $70.54 on Monday. Hologic, Inc. has a twelve month low of $66.58 and a twelve month high of $81.04. The company has a current ratio of 2.97, a quick ratio of 2.57 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $17.59 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 0.88 and a beta of 1.09. The firm has a 50-day moving average of $72.46 and a two-hundred day moving average of $72.81.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on HOLX shares. Bank of America lowered shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $81.00 to $75.00 in a research report on Wednesday, July 20th. StockNews.com started coverage on shares of Hologic in a research report on Thursday, March 31st. They issued a “buy” rating for the company. UBS Group started coverage on shares of Hologic in a research report on Wednesday, July 20th. They issued a “neutral” rating and a $73.00 target price for the company. SVB Leerink increased their target price on shares of Hologic to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, May 17th. Finally, Citigroup decreased their target price on shares of Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.63.
Insider Buying and Selling at Hologic
In other Hologic news, insider Jan Verstreken sold 6,500 shares of the company’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $78.80, for a total transaction of $512,200.00. Following the completion of the sale, the insider now directly owns 64,191 shares of the company’s stock, valued at $5,058,250.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.54% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- How to Find and Determine Which Stocks Are Worth Holding Through a Bear Market
- Trip Advisor Stock Might Be Ready for a Ride
- Snowflake Stock May Have Stopped Falling
- Three Watchlist Stocks to Capitalize on Sector Rotation
- MarketBeat: Week in Review 7/18 – 7/22
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.